Abstract:Abstract Background and Aims Chronic kidney disease (CKD) and heart failure share a complex, bidirectional interaction, and are therefore an area of crucial interest in nephrology due to their prevalence and effect on mortality. It is basic to identify the risk of heart failure in patients with CKD as soon as possible to improve treatment outcomes and complications. It is important to note that while there is wide experience in prediction of heart failure, the use of models based on artificial intelligence is practically non-existent with this objective in mind. Based on the experience of our group in the prediction of mortality in patients with CKD and in CKD progression with machine learning algorithms, this study aims to predict the onset of heart failure in CKD patients. This study addresses this issue using machine learning techniques to offer new opportunities for accurate prediction of cardiac disease. This approach facilitates the individualization of risk assessment and allows the implementation of early and personalized interventions that can significantly influence the management of both diseases. Method Design: Retrospective observational study of a historical cohort from the Registry of Renal Patients of Catalonia (RMRC) and the Catalan Agency for Health Quality and Evaluation. Sample: 5000 patients with CKD, selected for having the minimum number of missing data. Follow-up: 10 years, from January 2010 to December 2020. Inclusion criteria: patients older than 18 years with CKD. Variables: 333 variables: a) Age, gender, weight, height (4); b) Status on the transplant waiting list (2); c) Renal replacement therapy (3); d) Diagnoses (ICD-10) excluding group I50 diagnoses, used as the outcome (146); e) Laboratory variables (78); f) Pharmacological treatments (100). Label and models: The algorithm used was the Light Gradient Boosting Machine (LGBM), with which four models were trained to perform a binary classification to predict whether a patient would develop heart failure in a period of 3, 4, 5 or 6 years. Label 0 was used to represent the absence of heart failure, while label 1 was used to represent the presence of heart failure. The methodology used to train the models was as follows: 1. Pre-processing of the data to manage missing data and data errors. 2. Creating different datasets, one for each prediction horizon. 3. Training and evaluating the LGBM models (with 5-fold CV). Results Age: 63 ± 13 years, Gender: 66% male and 34% were female. Different prediction horizons were tested, and the best results were obtained for 6 years where was achieved an area under the curve of 0.86 and an accuracy of 0.76. The 5 variables with major relevance according to SHAP values (SHapley Additive exPlanations) and in this order are: age, CKD diagnosis, hypertension, haemoglobin, and lymphocytes. The results presented in Fig. 1 and Table 1 correspond to the mean obtained for the 5-folds of the Group Cross-Validation. Conclusion –Advanced artificial intelligence algorithms present promising results for the prediction of heart failure in CKD patients. –This enables early, personalized, and more effective treatments for CKD patients.

Multi‐variable biomarker approach in identifying incident heart failure in chronic kidney disease: results from the Chronic Renal Insufficiency Cohort study

Predicting Cardiovascular Mortality in Chronic Kidney Disease (CKD) Patients.

Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification

Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers

Determining Association between Fatal Heart Failure and Chronic Kidney Disease: A Machine Learning Approach

Chronic kidney disease and risk of atrial fibrillation and heart failure in general population‐based cohorts: the BiomarCaRE project

Exploring diagnostic biomarkers of type 2 cardio-renal syndrome based on secreted proteins and bioinformatics analysis

The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients

Cardiac Magnetic Resonance Assessment of Cardiac Function Across Chronic Kidney Disease Stages

#2277 Artificial Intelligence for predicting heart failure in chronic kidney disease: analysis of a 5000-patient cohort

Machine Learning-Based Mortality Prediction in Chronic Kidney Disease among Heart Failure Patients: Insights and Outcomes from the Jordanian Heart Failure Registry

Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Role of predictable biomarkers in early detection of cardiovascular events in Chronic Kidney Disease III and IV

Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD

Abstract 14014: Inclusion of Chronic Kidney Disease Measures Improves Heart Failure Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study

Multimodal predictions of end stage chronic kidney disease from asymptomatic individuals for discovery of genomic biomarkers

Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria

Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease

Predictive biomarkers for the early detection and management of heart failure

Strategies to Improve Monitoring Disease Progression, Assessing Cardiovascular Risk, and Defining Prognostic Biomarkers in Chronic Kidney Disease